Daria Zdżalik-Bielecka

Celon Pharma (Poland)

Daria Zdżalik-Bielecka's research contributes significantly to our understanding of the endocytic trafficking of gas6-Axl complexes and their association with sustained Akt activation. Their work also sheds light on the inhibition of cell growth by bemcentinib and gilteritinib, which impair endo-lysosomal and autophagy systems in an Axl-independent manner. Furthermore, Zdżalik-Bielecka's research highlights the potential of novel pyrazolo[1,5-a]pyrimidine derivatives as selective PI3Kδ inhibitors. The gas6-Axl signaling pathway has been linked to actin remodeling, driving membrane ruffling, macropinocytosis, and cancer-cell invasion, while also triggering DNA damage repair mechanisms.